All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

Autoria(s): Iland, Harry J.; Bradstock, Ken; Supple, Shane; Catalano, Alberto; Collins, Marnie; Hertzberg, Mark; Browett, Peter; Grigg, Andrew; Firkin, Frank; Hugman, Amanda; Reynolds, John; Di Iulio, Juliana; Tiley, Campbell; Taylor, Kerry; Filshie, Robin; Seldon, Michael; Taper, John; Szer, Jeff; Moore, John; Bashford, John; Seymour, John
Data(s)

23/08/2012
Identificador

http://hdl.handle.net/10536/DRO/DU:30060078
Idioma(s)

eng
Publicador

American Society of Hematology
Relação

http://dro.deakin.edu.au/eserv/DU:30060078/reynolds-alltransretinoicacid-2012.pdf

http://doi.org/10.1182/blood-2012-02-410746
Palavras-Chave #acute promyelocytic leukemia #trans-retinoic acid (ATRA) #anthracycline-based chemotherapy #arsenic trioxide (ATO) #APML4 phase 2 protocol #induction #consolidation
Tipo

Journal Article
Acesso ao item digital